US Edition
Big pharma holds its breath as Trump plots his revenge
The president wants to punish ‘rip-off’ drug giants. The world will pay the price
Advertisement
-
Fix the NHS or miss out on our money, US drug giant warns Britain
Interview: Eli Lilly plans to spend £279m on Britain – but UK boss Chris Stokes warns that might be it
-
Labour eyes ‘sovereign health fund’ as big pharma goes cold on Britain
Scheme would provide cash injection for a drugs industry facing £3.6bn NHS bill
-
Ireland can no longer rely on its charm to survive
The Taoiseach Micheál Martin is proving himself to be a grown-up leader in his dealings with Trump
-
The ‘dreadful’ decline of a British drug giant – and why RFK Jr could make it worse
Trump’s tariff threats and Kennedy’s anti-vaccine stance make US a hostile environment for pharma companies
-
‘We made 434pc on one stock – now we’re hunting for the next Ozempic’
Fund of the Week: manager of the UK’s top healthcare trust on how it beat FTSE by 220pc
-
How can a pharma company survive after its golden goose stops laying?
Despite patent expiries, AbbVie is on course for record sales
-
The NHS ‘double whammy’ undermining a £108bn British industry
Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower
-
AstraZeneca boss denies falling out with Labour despite scrapping £450m factory
Pascal Soriot says reports that relations with Whitehall have soured amount to fake news
-
Thomas Kingston’s parents speak of ‘great pain and grief’ at son’s death
The son-in-law of Prince and Princess Michael of Kent took his own life in February 2024
-
Revealed: 42 health conditions weight-loss jabs can improve… and 19 they make worse
Ozempic, Wegovy and Mounjaro can reduce risk of heart disease, dementia, and much more, says groundbreaking US study
-
‘Shark’ pharmaceutical companies not being honest about side effects, MPs warned
MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it evaluates
Advertisement
-
‘Ozempic face’ drives surge in sale of cosmetic fillers
Users of weight-loss drugs are seeking help from dermatologists to rectify ‘facial sagging’ after shedding the pounds
-
There is growth ahead for this pharma company as the takeover dust settles
Recent lacklustre performance offers an interesting buying opportunity
-
Ozempic maker’s shares plunge after failed weight-loss trial
Novo Nordisk’s disappointing results for a successor to Wegovy jab spooks investors
-
This tech stock is down by 75pc and isn’t recovering – it’s time to sell
But Questor has not given up hope on a promising pubs-to-hotels group that requires patience
-
UK women plan to sue Johnson & Johnson over talcum powder cancer claims
Claims of baby powder cancer link have already led pharmaceutical giant to pay out £7bn in the US
-
Trump’s latest cabinet pick threatens one of Britain’s few remaining industrial treasures
Life science giants are on the front lines of a fight fuelled by Kennedy’s quackery
-
Trump gets revenge on Pfizer with Robert F Kennedy Jr role
Pharma stocks slump following appointment of renowned vaccine sceptic
-
AstraZeneca’s £450m UK investment under review in state aid stand-off
Pharma giant pauses plans for Liverpool factory as it ‘reviews incentives’
-
AstraZeneca executive under investigation by police in China
Leon Wang detained as Beijing seeks to curb bribery and corruption in pharmaceutical industry
-
Workplaces are only human – we can’t run to employment tribunals whenever feelings get hurt
What you very much don’t want in a colleague is the sort of person who runs to an employment tribunal when their feelings get hurt
-
NHS cannot keep up with ‘tidal wave’ of demand for weight-loss jabs
Plans too slow despite Sir Keir Starmer’s belief the drugs ‘very important for economy’, campaigners say
